PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Bannon’s War Room | Morning Edition Hour 1 | Recorded March 16, 2021 | The Rot in the White House … Biden’s Moral Bankruptcy | Video: 48 Minutes 54 Seconds

Show Me

Biden In. ISIS Back. Isis-linked Militants Beheading Children in Mozambique, Says Aid Group

Show Me

Ballot Shredding (Destruction Of Evidence) Has Already Started In Georgia

Show Me

Georgia Judge Gives VOTER GA the Right to Inspect Fulton County Election Ballots

Show Me

AstraZeneca Vaccine Now Safe for Seniors, NACI Says

Show Me

Dem activists target Ga-based corporations in bid to oppose GOP voting reforms; Coke, Home Depot first to cave

Show Me

Trump Eyeing ‘Upgrade’ Over Georgia’s Gov. Kemp, Adviser Says

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 16, 2021 | Delete Your Account … Woke Corporations Fight Election Integrity and at Facebook | Video: 48 Minutes 55 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded March 16, 2021 | I’ll Bet You A Lot of Yuan … How Facebook and the Capitol Riot Stole the Election | Video: 49 Minutes

Show Me

Washington Post Blames Source for Falsified Trump Comments on Georgia Election

Show Me

Washington Post Admits to False Trump Quote

Show Me

U.S. Lawyer Steven Donziger Speaks from House Arrest in NYC After Suing Chevron for Amazon Oil Spills

Show Me

Georgia Judge Might Unseal Fulton County Absentee Ballots for Fraud Investigation

Show Me

Italy Prosecutors Seize Batch of AstraZeneca Vaccine After Death of Man

Show Me

News Corp. agrees to three-year deal with Facebook in Australia

Show Me

After 18 Years, Billion-Dollar Bioterror Defense System Still Can’t Detect Multiple Threats

Show Me

Myanmar: Vast arsenal and notorious troops deployed during nationwide ‘killing spree’ protest crackdown – new research

Show Me

Judicial Watch: Federal Court Slams Potentially Illicit Sales of Body Parts of Aborted Fetuses – Orders Release of Additional Information on Organ Purchases

Show Me

China in Focus (March 15): Biden White House Officials Recognize Lab Leak Theory

Show Me

NY Legislature Proposes Nearly $7 Billion in New Taxes on Businesses, Wealthy

Show Me

150 Spring Breakers Arrested in Miami Beach

Show Me

Investigation Against Gov. Cuomo Intensifies As Accuser Submits To Lengthy 4-Hour Interview

Show Me

March 15, 2021 | Nightly News Rebroadcast | Video: 55 Minutes 03 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded March 15, 2021 | God’s Timing … Mike Lindell on His Political Future, Fake News, and Fraud | Video: 48 Minutes 50 Seconds

Show Me

Duke University Imposes Stay-In-Place Order for Undergraduates, Cites Party-Linked COVID-19 Surge

Show Me

BLM activist Tamika Mallory calls out Joe Biden and ‘demands justice’ during Grammys

Show Me

Las Vegas swarmed with crowds as casinos reopen at 50 percent capacity

Show Me

Fauci Fears Another COVID-19 Surge, Says Trump Should Tell Supporters to Get Vaccinated

Show Me

National Guard identifies solider who died off duty while deployed at U.S. Capitol

Show Me

Fauci documentary marks AP foray into film

Show Me

Doctors Are Investigated After Posting Organ Photos Online as ‘Price Is Right’ Game

Show Me

Woman fatally shot by cop in traffic stop-turned-shootout in Tennessee

Show Me

NEW George Floyd Riots: What the Media ISN’T Telling You! (SHOW NOTES)

Show Me

Elon Musk Gets New Title of ‘Technoking of Tesla’

Show Me

Watchdog group says three House Democrats broke ethics rules by linking member, campaign sites

Show Me

MyPillow CEO Says New App Will Be ‘Safe Place’ for Those Canceled by YouTube, Twitter

Show Me

Danish Woman Who Died From Blood Clot After AstraZeneca Shot Had ‘Unusual Symptoms’, Agency Says

Show Me

Opportunity Beckons in the Mideast

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded March 15, 2021 | The Ides of March … Populism Then and Now | Video: 48 Minutes 48 Seconds

Show Me

Judicial Watch to Facebook: End Censorship of Trump

Show Me